New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates.

The development of new therapeutic agents against malaria has become urgent during the past few decades, due to an increased prevalence of drug-resistant strains of malaria-causing Plasmodium parasites. Possible targets are the hemoglobin-degrading aspartic proteases, the plasmepsins. While acyclic alpha,alpha-difluoroketone hydrates have been introduced into peptidomimetics to bind to the catalytic Asp dyad of aspartic proteases, alicyclic derivatives were unknown. This paper describes a versatile synthesis of hydrated alicyclic alpha,alpha-difluoro-cyclopentanones and -cyclohexanones, decorated with appropriate substituents to fill the S1/S3 and the "flap-open" pocket at the enzyme active sites. Their biological activity was tested against plasmepsin II and IV, revealing an IC(50) value (concentration of an inhibitor at which 50% maximum initial velocity is observed) of 7 microM for the best ligand. Reference inhibitors with a protonated secondary ammonium centre to address the catalytic dyad showed similar binding affinities. The X-ray crystal structure of a cyclic alpha,alpha-difluoroketone hydrate revealed the ability of these novel building blocks to participate in H-bonding networks. The hydration of difluoroketones was also investigated in solution. An exemplary study showed that the equilibrium constants for the hydration of alpha,alpha-difluorinated cyclohexanones are much higher than those for the corresponding cyclopentanones.

[1]  M. Bottomley,et al.  Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding Domain* , 2008, Journal of Biological Chemistry.

[2]  J. Cooper,et al.  The catalytic mechanism of an aspartic proteinase explored with neutron and X-ray diffraction. , 2008, Journal of the American Chemical Society.

[3]  F. Diederich,et al.  Exploring the Flap Pocket of the Antimalarial Target Plasmepsin II: The “55 % Rule” Applied to Enzymes , 2008, ChemMedChem.

[4]  F. Diederich,et al.  Fluorine in Pharmaceuticals: Looking Beyond Intuition , 2007, Science.

[5]  Manfred Kansy,et al.  Predicting and Tuning Physicochemical Properties in Lead Optimization: Amine Basicities , 2007, ChemMedChem.

[6]  M. Schlitzer,et al.  Malaria Chemotherapeutics Part I: History of Antimalarial Drug Development, Currently Used Therapeutics, and Drugs in Clinical Development , 2007, ChemMedChem.

[7]  Y. Ebizuka,et al.  Actinorhodin biosynthesis: structural requirements for post-PKS tailoring intermediates revealed by functional analysis of ActVI-ORF1 reductase. , 2007, Biochemistry.

[8]  L. Prade,et al.  Achiral, Cheap, and Potent Inhibitors of Plasmepsins I, II, and IV , 2006, ChemMedChem.

[9]  F. Diederich,et al.  Starving the malaria parasite: inhibitors active against the aspartic proteases plasmepsins I, II, and IV. , 2006, Angewandte Chemie.

[10]  L. Prade,et al.  X-ray Structure of Plasmepsin II Complexed with a Potent Achiral Inhibitor* , 2005, Journal of Biological Chemistry.

[11]  François Diederich,et al.  Orthogonal multipolar interactions in structural chemistry and biology. , 2005, Angewandte Chemie.

[12]  S. Hay,et al.  The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.

[13]  Jun Liu,et al.  The Role of Plasmodium falciparum Food Vacuole Plasmepsins* , 2005, Journal of Biological Chemistry.

[14]  J. Dame,et al.  Genetic Disruption of the Plasmodium falciparum Digestive Vacuole Plasmepsins Demonstrates Their Functional Redundancy* , 2004, Journal of Biological Chemistry.

[15]  C. Tanyeli,et al.  Chemoenzymatic synthesis of a '- and a-acetoxylated cyclic ketones , 2004 .

[16]  L. Toupet,et al.  A difluorosulfide as a Freon-free source of phosphonodifluoromethyl carbanion. , 2003, Organic & biomolecular chemistry.

[17]  J. Cooper,et al.  The structure of endothiapepsin complexed with the gem-diol inhibitor PD-135,040 at 1.37 A. , 2003, Acta crystallographica. Section D, Biological crystallography.

[18]  Jun Liu,et al.  Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Steiner.  The hydrogen bond in the solid state. , 2002, Angewandte Chemie.

[20]  L. Reeves,et al.  Difluoroketones as inhibitors of matrix metalloprotease-13. , 2000, Bioorganic & medicinal chemistry letters.

[21]  J. Guthrie.  Hydration of Carbonyl Compounds, an Analysis in Terms of Multidimensional Marcus Theory , 2000 .

[22]  Maria Cristina Burla,et al.  SIR97: a new tool for crystal structure determination and refinement , 1999 .

[23]  T. Blundell,et al.  The three-dimensional structure at 2.4 A resolution of glycosylated proteinase A from the lysosome-like vacuole of Saccharomyces cerevisiae. , 1997, Journal of molecular biology.

[24]  Paul R. Gerber,et al.  MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..

[25]  P. Bernstein,et al.  Examination of peptidic α′,β-diamino-α,α-difluoroketones as inhibitors of human leukocyte elastase , 1994 .

[26]  Michael H. Gelb,et al.  Crystallographic analysis of transition state mimics bound to penicillopepsin: difluorostatine- and difluorostatone-containing peptides. , 1994 .

[27]  S. Vasavanonda,et al.  Pseudo‐symmetrical difluoroketones , 1993, FEBS letters.

[28]  C. Tarnus,et al.  MDL 74147, a novel selective and soluble inhibitor of human renin. Synthesis, structure-activity relationship, species and protease selectivities. , 1992 .

[29]  T L Blundell,et al.  Direct observation by X‐ray analysis of the tetrahedral “intermediate” of aspartic proteinases , 1992, Protein science : a publication of the Protein Society.

[30]  S. Ghosh,et al.  A chemoenzymatic approach to (R)-tetrahydro-5-oxo-2-(2-hydroxyethyl)furan, a useful chiral synthon: Application to the synthesis of (S)-4-hexanolide, pheromone antipode of . , 1991 .

[31]  C. Debouck,et al.  Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G. A. Jeffrey.  Water structure in organic hydrates , 1969 .

[33]  Bruno Martoglio,et al.  Aspartic proteases in drug discovery. , 2007, Current pharmaceutical design.

[34]  R E Cachau,et al.  Inhibition and catalytic mechanism of HIV-1 aspartic protease. , 1996, Journal of molecular biology.

[35]  R. Chambers,et al.  Elemental fluorine. Part 6. Fluorination of cyclic 1,3-diketones and related compounds , 1996 .

[36]  Stephen P. Miller,et al.  Synthesis and inhibitory activity of difluoroketone substrate analogs of N-myristoyltransferase. , 1994 .

[37]  A. Doherty,et al.  Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors. , 1992, Journal of medicinal chemistry.

[38]  R. Bell,et al.  The hydration of acetaldehyde in aqueous solution , 1952 .